| 000 | 01126 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250516041347.0 | ||
| 264 | 0 | _c20110817 | |
| 008 | 201108s 0 0 eng d | ||
| 022 | _a1529-0131 | ||
| 024 | 7 |
_a10.1002/art.30225 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWard, Michael M | |
| 245 | 0 | 0 |
_aSulfasalazine for the treatment of ankylosing spondylitis: relic or niche medication? _h[electronic resource] |
| 260 |
_bArthritis and rheumatism _cJun 2011 |
||
| 300 |
_a1472-4 p. _bdigital |
||
| 500 | _aPublication Type: Comment; Editorial; Research Support, N.I.H., Intramural | ||
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aEtanercept |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunoglobulin G _xtherapeutic use |
| 650 | 0 | 4 | _aRandomized Controlled Trials as Topic |
| 650 | 0 | 4 |
_aReceptors, Tumor Necrosis Factor _xtherapeutic use |
| 650 | 0 | 4 |
_aSpondylitis, Ankylosing _xdrug therapy |
| 650 | 0 | 4 |
_aSulfasalazine _xtherapeutic use |
| 773 | 0 |
_tArthritis and rheumatism _gvol. 63 _gno. 6 _gp. 1472-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/art.30225 _zAvailable from publisher's website |
| 999 |
_c20890058 _d20890058 |
||